Alzchem Group AG posted Q1 sales €148.7 million, 2.7% YoY growth but €1.1 million below consensus €149.8 million for the quarter.
EBITDA rose 18% to €32.3 million and EBIT increased 23% to €25.6 million, both surpassing analyst expectations for Q1 2026.
EPS climbed 23% to €1.77 versus €1.65 consensus; free cash flow dropped to €1.1 million from €36.4 million a year earlier.
Alzchem reaffirmed FY2026 guidance of ~€600 million sales (+7%) and €126 million EBITDA (+8%), with capacity expansions slated for H2 2026/2027.